Hercep test applied in mammary tumors in female dogs;Der hercep test in anwendung bei mammatumoren der hündin

Kleintierpraxis

Volumn 50, Issue 4, 2005, Pages 221-226

  Kott, Christiane ^a   Mätz Rensing, Kerstin ^a   Kaup, Franz Josef ^a  

^a GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOG; FEMALE; HERCEP TEST; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; SCREENING TEST; SQUAMOUS CELL CARCINOMA;

CANIS FAMILIARIS;

EID: 18644371897     PISSN: 00232076     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. AHERN, T. E., R. C. BIRD, A. E. CHURCH BIRD und L. G. WOLFE (1996): Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am. J. Vet. Res. 57, 693-696.
2. BLOOM, K. J., H. GOVIL, P. GATTUSO, V. REDDY und D. FRANCESCATTI (2001): Status of HER-2 in male and female breast carcinoma. Am. J. Surg. 182, 389-392.
3. BRODEY, R. S., M. H. GOLDSCHMIDT und J. R. ROSZEL (1983): Canine mammary gland neoplasms. J. Am. Anim. Hosp. Assoc. 19, 61-90.
4. DE LAS MULAS, J. M., J. ORDAS, Y. MILLAN, V. FERNANDEZ-SORIA und S. R. CAJAL (2003): Oncogene HER-2 in canine mammary gland carcinomas. Breast Cancer Res. Treat. 80, 363-367.
5. HYNES, N. E., und D. F. STERN (1994): The biology of erbB-2/neu/HER2 and its role in cancer. Biochim. Biophys. Acta Rev. Cancer 1198, 165-184.
6. KAUFMANN, M., und L. KANZ (2000): Immuntherapie der Mammakarzinome mit Herceptin: Zweiter Expertenworkshop "Neue Entwicklungen bei der Therapie des metastasierten Mammakarzinoms". Dtsch. Ärztebl. 97, A 844-847.
7. KLAPPER, L N., M. H. KIRSCHBAUM, M. SELA und Y. YARDEN (2000): Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25-79.
8. KOTT, C. (2004): Zur Aussagekraft der HER2 Rezeptorexpression in caninen Mammatumoren als diagnostischer und prognostischer Faktor. Hannover, Tierärztl. Hochsch., Diss.
9. McKEAGE, K., und C. M. PERRY (2002): Ein Überblick über die Anwendung in der Behandlung des metastasierten Mammakarzinoms bei HER2-Überexpression. Drugs 62, 209-248.
10. MENARD, S., S. M. PUPA, M. CAMPIGLIO und E. TAGLIABUE (2003): Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570-6578.
11. MISDORP, W., R. W. ELSE, E. HELLMEN und T. P. LIPSCOMB (1999): Histological classification of mammary tumors of the dog and the cat. Washington, D. C., Second series, Volume VII.
12. RENNER, C., F. HARTMANN und M. PFREUNDSCHUH (2002): Immuntherapeutische Strategien zur Behandlung solider Tumoren. Dtsch. Ärztebl. 99, A 850-858.
13. RUNGISPIPAT, A., S. TATEYAMA, R. YAMAGUCHI, K. UCHIDA, N. MIYOSHI und T. HAYASHI (1999): Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J. Vet. Med. Sci. 61, 27-32.
14. SCHOLL, S., P. BEUZEBOC und P. POUILLART (2001): Targeting HER2 in other tumor types. Ann. Oncol. 12, 81-87.
15. SHEPARD, H. M., G. D. LEWIS, J. C. SARUP, B. M. FENDLY, D. MANEVAL, J. MORDENTI, I. FIGARI, C. E. KOTTS, M. A. PALLADINO, JR., A. ULLRICH und D. SLAMON (1991): Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-127.
16. SLAMON, D. J., G. M. CLARK, S. G. WONG, W. J. LEVIN, A. ULLRICH und L McGUIRE (1987): Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu Oncogene. Science 235, 177-182.
17. SLAMON, D. J., W. GODOLPHIN, L. A. JONES, J. A. HOLT, S. G. WONG, D. E. KEITH, W. J. LEVIN, S. G. STUART, J. UDOVE, A. ULLRICH und M. F. PRESS (1989): Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.